Aduhelm decision will ‘chill’ innovation, say BIO experts
This month’s decision by the U.S. Centers for Medicare & Medicaid Services (CMS) to limit coverage of the Alzheimer’s drug Aduhelm to patients enrolled in […]
Aduhelm decision will ‘chill’ innovation, say BIO experts Read More »